Dr. rer. nat. Paolo Mazzeo - Department of Hematology and Medical Oncology

Paolo Mazzeo completed his MSc in Medical and Pharmaceutical Biotechnology at the University of Florence and obtained his PhD / Dr. rer. nat. in Molecular Medicine at the University of Göttingen. He is currently a postdoctoral fellow at the INDIGHO Laboratory (Prof. Dr. Detlef Haase) and AG Koch (PD Dr. Raphael Koch) at the Department of Hematology and Medical Oncology of the University Medical Center Göttingen

During his doctoral training, his scientific focus was on clonal evolution and therapy resistance in myeloid malignancies, with particular emphasis on integrating longitudinal genomic profiling with functional apoptosis analyses. He developed translational approaches that combine molecular diagnostics and functional apoptosis profiling to characterize treatment-associated genetic evolution and anti-apoptotic dependencies in high-risk myelodysplastic syndromes and acute myeloid leukemia, as a basis for personalized, novel therapeutic approaches.

In his current project, he investigates the treatment-associated genomic and functional evolution of myeloid neoplasms through longitudinal patient sampling and integrative multi-omics. The project combines comprehensive molecular genetics and cytogenetic profiling, functional apoptosis profiling, and advanced bioinformatics to define mechanisms of clonal evolution, therapy adaptation, and resistance. Single-cell transcriptomic approaches are applied to resolve cellular heterogeneity and microenvironmental interactions, while translational strategies focus on developing personalized therapeutic concepts. Functional validation is performed through ex vivo drug testing and dynamic BH3 profiling, aiming to establish an integrated precision medicine framework for individualized therapy selection.

Dr. rer. nat. Ali Harb - Department of Anesthesiology

Ali Harb completed his PhD studies in the field of neuroscience at the University of Saarland in 2019, and works since June 2021 as a Postdoc in the Anaesthesiology Department at the UMG in Göttingen. 

Out-of-hospital cardiac arrest is associated with survival rates below 10%, with post-cardiac arrest brain injury representing a major determinant of poor neurological outcome. In addition to ischemic damage, reperfusion during cardiopulmonary resuscitation (CPR) induces profound mitochondrial dysfunction and excessive production of reactive oxygen species (ROS), largely driven by succinate accumulation and reverse electron transport at mitochondrial complex I. These processes critically contribute to successive synaptic dysfunction, neuroinflammation, neuronal death, and long-term cognitive impairment.

This project examines transient modulation of succinate metabolism via inhibition of mitochondrial complex II as a strategy to reduce reperfusion-associated ROS production. Although pharmacological complex II inhibition, exemplified by compounds such as the reversible inhibitor malonate, have shown cardioprotective effects in ischemia-reperfusion injury, their neuroprotective potential in global cerebral ischemia after cardiac arrest remains largely unexplored.

Using an established preclinical rat model of asphyxia-induced cardiac arrest and resuscitation, this study will evaluate whether transient complex II modulation administered alongside standard CPR reduces oxidative stress, preserves mitochondrial and synaptic function, and limits neuronal injury. Leveraging his expertise in synaptic and neuronal studies at the cellular and tissue levels, Dr. Harb will investigate how mitochondrial metabolic control influences synaptic integrity, neuronal survival, and network-level function in vulnerable brain regions. By integrating mechanistic analyses with neurological outcome measures, this work aims to define complex II modulation as a rational, translatable therapeutic target to improve brain recovery after cardiac arrest.

Dr. rer. nat. Lukas Grimm - Institute for Neuroimmunology & Multiple Sclerosis Research

Lukas Grimm received his PhD in 2024 for his work at the Institute for Neuroimmunology & Multiple Sclerosis Research at the University of Göttingen. He is currently continuing his research as a postdoctoral fellow in the institute of Prof. Alexander Flügel.

In multiple sclerosis, immune cells that recognize self-antigens in the central nervous system damage neurons and their myelin sheaths. Neurodegeneration is associated with increased disease burden and progression. Recent findings suggest direct pathological interactions between autoreactive T cells and neurons.

Lukas Grimm’s research investigates the mechanisms underlying T-cell-driven inflammatory processes in the central nervous system. His current project focuses in particular on the direct interplay between autoreactive T cells and neurons. Using targeted genetic manipulation, he aims to modulate the bond between T cells and neurons in order to better understand the functional significance of their interaction.

Dr. Mariano Barbieri - Institute of Pathology

Mariano Barbieri completed his studies in Applied Physics in 2013 at the ‘Federico II’ University of Naples and moved to Berlin at the Max Delbrück Center for Molecular Medicine to develop structural models of gene transcription regulation in mESC. Progressively, he shifted his research interest towards human disease, senescence and cancer, moving to University Medical Center Göttingen in 2021 in the Pathology Department.

His research interest lies in the chromatin-protein interactions underlying the transcriptional program, in order to predict the functional effect of their disruption upon malignancy insurgence. In particular, he has devised a suite of computational approaches which integrates multi-omics data to predict chromatin structural features, and applied it to Glioblastoma multiforme to predict enhancer-promoter hijacking events upon genome tumorigenic structural variation associated with MYC oncogene over-expression. 

The aim of his project is to apply this methodology to PDAC patients to identify the patient-specific pathogenic pathways and subpopulation structures, in order to promote more precise medical treatments in the perspective of the digitalized and personalized medicine.